Synlogic Inc (SYBX)

$0.62 +0.06 (10.71%)
Market Cap 6.55M
Revenue (ttm) 10,000.00
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233,600.01%
Debt to Equity Ratio 0.00
Volume 347,600
Avg Vol 121,768
Day's Range N/A - N/A
Shares Out 11.70M
Stochastic %K 9%
Beta 0.39
Analysts Strong Buy
Price Target $1.00

Company Profile

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 659 2802
Address:
PO Box 30, Winchester, United States
NVDAMillionaire
NVDAMillionaire Jun. 10 at 1:32 PM
$SYBX Brilliant piece that captures SYBX's situation perfectly. So if you want to update your understanding of SYBX or get to know SYBX better, this is essential reading. https://everyticker.com/quote/SYBX/analysis/synlogic-a-7-7m-lottery-ticket-on-synthetic-biology-s-graveyard-nasdaq-sybx
0 · Reply
youspeaktome
youspeaktome Feb. 18 at 2:11 PM
$SYBX We have $SNSE up 250% this morning because they chose to do something but Synlogic is ran by the dumbest and laziest biotech executive ever Mary Beth Dooley so we get screwed and our stock is delisted because she chose to do nothing for 2 years but steal the cash.
0 · Reply
RiskDrifter
RiskDrifter Feb. 18 at 10:21 AM
$SYBX Oncology biotech with high-risk development profile.
0 · Reply
youspeaktome
youspeaktome Jan. 23 at 7:55 PM
$SYBX Mary Beth Dooley has been at Synlogic since June 2018 and has been collecting a fat salary and stock for over 7 years now while the company craters. Her entire compensation will be more than the current market cap. Disgusting. Her current comp is $425K doing jack all but stealing the rest of the cash.
0 · Reply
Chrissytina
Chrissytina Jan. 21 at 7:14 PM
$SYBX Can some please tell me how the F*ck can Stocktwits have this pos bullish??? Wtf
0 · Reply
youspeaktome
youspeaktome Jan. 21 at 4:13 PM
$SYBX Synlogic had 2 years to look for strategic alternatives and they sat around doing nothing but collect fat salaries. List of brain dead executive and board members: Mary Beth Dooley Peter Barrett, Ph.D. (Chairman of the board) James Flynn (Director) Edward Mathers (Director) Richard P. Shea (Director) All of the above should be banned forever from being an executive or serving on a public board. They couldn't even bother to do a digital asset treasury. Mary Beth Dooley gets paid $325K in salary for doing nothing for 2 years. That's $750K direct to her for thieving.
0 · Reply
Crazy_Gambler
Crazy_Gambler Jan. 21 at 9:12 AM
$LGHL ALERT SHORT SQUEEZE !!! Tiny Float Tiny Cap highly shorted. No sellers. Short Squeeze imminent. Come grab free money. $SYBX $LHAI $PN
1 · Reply
lecorb
lecorb Jan. 20 at 11:31 PM
$SDEV $SYBX $LHAI $$VERO $JAGX & More! Big Day Crabs!
0 · Reply
stockanalysis_
stockanalysis_ Jan. 20 at 2:13 PM
Premarket Losers: $VERO $SYBX $JAGX $TORO $NIVF Bookmark this screener: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
0 · Reply
CollateralCallC
CollateralCallC Dec. 26 at 4:05 PM
$SYBX Conditions are shifting toward markets rewarding operational proof over narrative ambition. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. The forward path ultimately depends on disciplined delivery.
0 · Reply
Latest News on SYBX
No data available.
NVDAMillionaire
NVDAMillionaire Jun. 10 at 1:32 PM
$SYBX Brilliant piece that captures SYBX's situation perfectly. So if you want to update your understanding of SYBX or get to know SYBX better, this is essential reading. https://everyticker.com/quote/SYBX/analysis/synlogic-a-7-7m-lottery-ticket-on-synthetic-biology-s-graveyard-nasdaq-sybx
0 · Reply
youspeaktome
youspeaktome Feb. 18 at 2:11 PM
$SYBX We have $SNSE up 250% this morning because they chose to do something but Synlogic is ran by the dumbest and laziest biotech executive ever Mary Beth Dooley so we get screwed and our stock is delisted because she chose to do nothing for 2 years but steal the cash.
0 · Reply
RiskDrifter
RiskDrifter Feb. 18 at 10:21 AM
$SYBX Oncology biotech with high-risk development profile.
0 · Reply
youspeaktome
youspeaktome Jan. 23 at 7:55 PM
$SYBX Mary Beth Dooley has been at Synlogic since June 2018 and has been collecting a fat salary and stock for over 7 years now while the company craters. Her entire compensation will be more than the current market cap. Disgusting. Her current comp is $425K doing jack all but stealing the rest of the cash.
0 · Reply
Chrissytina
Chrissytina Jan. 21 at 7:14 PM
$SYBX Can some please tell me how the F*ck can Stocktwits have this pos bullish??? Wtf
0 · Reply
youspeaktome
youspeaktome Jan. 21 at 4:13 PM
$SYBX Synlogic had 2 years to look for strategic alternatives and they sat around doing nothing but collect fat salaries. List of brain dead executive and board members: Mary Beth Dooley Peter Barrett, Ph.D. (Chairman of the board) James Flynn (Director) Edward Mathers (Director) Richard P. Shea (Director) All of the above should be banned forever from being an executive or serving on a public board. They couldn't even bother to do a digital asset treasury. Mary Beth Dooley gets paid $325K in salary for doing nothing for 2 years. That's $750K direct to her for thieving.
0 · Reply
Crazy_Gambler
Crazy_Gambler Jan. 21 at 9:12 AM
$LGHL ALERT SHORT SQUEEZE !!! Tiny Float Tiny Cap highly shorted. No sellers. Short Squeeze imminent. Come grab free money. $SYBX $LHAI $PN
1 · Reply
lecorb
lecorb Jan. 20 at 11:31 PM
$SDEV $SYBX $LHAI $$VERO $JAGX & More! Big Day Crabs!
0 · Reply
stockanalysis_
stockanalysis_ Jan. 20 at 2:13 PM
Premarket Losers: $VERO $SYBX $JAGX $TORO $NIVF Bookmark this screener: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading
0 · Reply
CollateralCallC
CollateralCallC Dec. 26 at 4:05 PM
$SYBX Conditions are shifting toward markets rewarding operational proof over narrative ambition. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. The forward path ultimately depends on disciplined delivery.
0 · Reply